Itsuko Miyazawa

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Hideka Inoue, Katsutaro Morino, Satoshi Ugi et al. · Journal of Diabetes Investigation · 2018 · 59 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Relationship of Insulin Resistance to Prevalence and Progression of Coronary Artery Calcification Beyond Metabolic Syndrome Components

Masahiro Yamazoe, Takashi Hisamatsu, Katsuyuki Miura et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2016 · 58 citations

Medicine, Cardiology, Endocrinology +16

The Prognosis of Patients With Type 2 Diabetes and Nonalbuminuric Diabetic Kidney Disease Is Not Always Poor: Implication of the Effects of Coexisting Macrovascular Complications (JDDM 54)

Hiroki Yokoyama, Shin‐ichi Araki, Koichi Kawai et al. · Diabetes Care · 2020 · 58 citations

Medicine, Internal Medicine, Nephrology +16